Scribe Therapeutics advances STX-1150 Phase 1 trial, expands Sanofi deal
The gene-editing company reported continued enrollment in its lead cardiovascular program and said cash on hand funds operations into the first half of 2029.
SEC filing
2 stories
The gene-editing company reported continued enrollment in its lead cardiovascular program and said cash on hand funds operations into the first half of 2029.
SEC filing
Cardiovascular gene-editing company reports first clinical data expected in H1 2027 and cash runway into H1 2029 after $155.5 million IPO and Sanofi private placement.
SEC filing